Amphastar Pharmaceuticals (AMPH) News
NASDAQ: AMPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
28.25+0.14 (+0.50%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AMPH news summary
We found 10 recent headlines mentioning Amphastar Pharmaceuticals (AMPH): 0 in the past week and 6 in the past 30 days, most often from Nasdaq, PR Newswire. For price context, AMPH is up 0.50% at $28.25. The most recent story, "Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London", was published by PR Newswire on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Amphastar Pharmaceuticals headlines
- Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonRANCHO CUCAMONGA, Calif., Nov. 11, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration,…PR Newswire
- Amphastar Pharmaceuticals Consensus Price Target Increased 12.34% to $25.78The average one-year price target for Amphastar Pharmaceuticals (NASDAQGS:AMPH) (DB:29A) has been revised to $25.78 / share as of November 6, 2026. This is an increase of 12.34% from the prior…Nasdaq
- Amphastar (AMPH) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqAMPH, ET
- Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026Net revenues of $207.6 million for the three months ended September 30, 2026 GAAP net income of $37.8 million, or $0.87 per share, for the third quarter Adjusted non-GAAP net income of $49.3 million,…PR Newswire
- BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue EstimatesBridgeBio Pharma (BBIO) delivered earnings and revenue surprises of +30.00% and +19.08%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqBBIO, AMPH
- Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended…PR Newswire
- Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and ViatrisAmphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.NasdaqAMPH, VTRS
- 3 Generic Drug Stocks to Watch Amid Improving Industry TrendsThe Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.NasdaqAMPH, VTRS
- New Strong Sell Stocks for August 14thAMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.NasdaqHE, AMPH, CHT
- AMPH vs. RDY: Which Stock Should Value Investors Buy Now?AMPH vs. RDY: Which Stock Is the Better Value Option?NasdaqAMPH, RDY